Clinical Research Directory
Browse clinical research sites, groups, and studies.
Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
Sponsor: Fudan University
Summary
A multi-center, real world study to evaluate the clinical outcomes and safety of Abemaciclib, Palbociclib or Dalpiciclib combined with endocrine therapy as first-line treatment in HR Positive, HER2 Negative unresectable or metastatic Breast Cancer.
Official title: A Multi-center Study of the Clinical Outcomes of Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer in Real World Practice
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2023-05-20
Completion Date
2025-02-01
Last Updated
2024-12-20
Healthy Volunteers
No
Conditions
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China